Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study
Published Online: 2021-07-?
Journal: The Lancet Oncology•Publisher: Elsevier BV
Authors: Aibing Xu•Baocai Xing•Baorui Liu•Bixiang Zhang•Chao Liu•Chengyou Du•Feng Xia•Gaojun Teng•Guoliang Shao•Guowen Yin•Hui Zhou•Jia Fan•Jian Wu•Jianbing Wu•Jianming Xu•Jinhai Wang•Jiuwei Cui•Junye Wang•Ming Huang•Mingxia Chen•Qiu Li•Shanzhi Gu•Shundong Cang•Tao Yin•Wei Yang•Weidong Jia•Xuetao Shi•Yabing Guo•Yajin Chen•Yan Wang•Yanru Qin•Yilei Mao•Yinying Lu•Yong Yang•Yunfeng Shan•Yuxian Bai•Zhendong Chen•Zhenggang Ren•Zhenyuan Gao•Zhiqiang Meng
